hotspot -WSS

hotspot

author：hotspot 2025-09-10 05:02:40 - browse：89

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Food makers to regulators: Ultra

WSS

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

FDA approves updated Covid vaccines

PEPFAR is under serious threat — and so is global health

Supreme Court rules employers must be more accommodating of religious observance

Here's how to stay safe from wildfire smoke amid reduced air quality

Why do we get seasonal allergies?

explore

hotspot

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

ChatGPT in medicine: STAT answers readers' burning questions

IRA could hurt research into orphan drugs for rare diseases

Psychedelics group wrestles with new pharma identity

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

How one medical school became remarkably diverse

Synthetic human embryos? Researchers say term is overblown

The high cost of giving birth even with insurance

Ukrainian soldiers say they owe lives to US

hotspot

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Synthetic human embryos? Researchers say term is overblown

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Generate Biomedicines machine learning biotech raises $273M

Brazil's Jair Bolsonaro is barred from running for office until 2030

hotspot

focus

hotspot

focus